{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:44:29Z","timestamp":1788903869669,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M711909"],"award-info":[{"award-number":["2022M711909"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2022MH068"],"award-info":[{"award-number":["ZR2022MH068"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shandong Provincial Traditional Chinese Medicine Technology Project","award":["Q-2022066"],"award-info":[{"award-number":["Q-2022066"]}]},{"DOI":"10.13039\/501100020196","name":"Shandong Provincial Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["SDCX-ZG-202203066"],"award-info":[{"award-number":["SDCX-ZG-202203066"]}],"id":[{"id":"10.13039\/501100020196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical application of conventional doxorubicin (CDOX) was constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet been comprehensively evaluated in clinical settings. The FAERS data from January 2004 to December 2022 were collected to analyze the adverse events of liposomal doxorubicin and CDOX. Disproportionate analysis and Bayesian analysis were employed to quantify this association. Our analysis incorporated 68,803 adverse event reports related to Doxil\/Caelyx, Myocet and CDOX. The relative odds ratios (RORs, 95%CI) for febrile neutropenia associated with CDOX, Doxil\/Caelyx, and Myocet were 42.45 (41.44; 43.48), 17.53 (16.02; 19.20), and 34.68 (26.63; 45.15) respectively. For cardiotoxicity, they were 38.87(36.41;41.49), 17.96 (14.10; 22.86), and 37.36 (19.34; 72.17). For Palmar-Plantar Erythrodysesthesia (PPE), the RORs were 6.16 (5.69; 6.68), 36.13 (32.60; 40.06), and 19.69 (11.59; 33.44). Regarding onset time, significant differences adverse events including neutropenia, PPE, pneumonia and malignant neoplasm progression. This study indicates that clinical monitoring for symptoms of cardiotoxicity of CDOX and Myocet, and PPE and interstitial lung disease of Doxil should be performed. Additionally, the onset time of febrile neutropenia, malignant neoplasm progression, and pneumonia associated with Doxil and Myocet merits particular attention. Continuous surveillance, risk evaluations, and additional comparative studies between liposomal doxorubicin and CDOX were recommended.<\/jats:p>","DOI":"10.1038\/s41598-024-55185-4","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T05:02:27Z","timestamp":1709269347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins"],"prefix":"10.1038","volume":"14","author":[{"given":"Huiling","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riran","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"55185_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","volume":"65","author":"O Tacar","year":"2013","unstructured":"Tacar, O., Sriamornsak, P. & Dass, C. R. Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65, 157\u2013170. https:\/\/doi.org\/10.1111\/j.2042-7158.2012.01567.x (2013).","journal-title":"J. Pharm. Pharmacol."},{"key":"55185_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells12040659","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk, M. et al. Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells. 12, 659. https:\/\/doi.org\/10.3390\/cells12040659 (2023).","journal-title":"Cells."},{"key":"55185_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100047","volume":"2","author":"K Sahu","year":"2021","unstructured":"Sahu, K., Langeh, U., Singh, C. & Singh, A. Crosstalk between anticancer drugs and mitochondrial functions. Curr. Res. Pharmacol. Drug Discov. 2, 100047. https:\/\/doi.org\/10.1016\/j.crphar.2021.100047 (2021).","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"55185_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6 (2004).","journal-title":"Pharmacol. Rev."},{"key":"55185_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-1-4419-6306-219","volume":"678","author":"CD Aluise","year":"2010","unstructured":"Aluise, C. D. et al. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: Role of cytokine-induced, oxidative\/nitrosative stress in cognitive dysfunction. Adv. Exp. Med. Biol. 678, 147\u2013156. https:\/\/doi.org\/10.1007\/978-1-4419-6306-219 (2010).","journal-title":"Adv. Exp. Med. Biol."},{"key":"55185_CR6","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho, C. et al. Doxorubicin: The good, the bad and the ugly effect. Curr. Med. Chem. 16, 3267\u20133285. https:\/\/doi.org\/10.2174\/092986709788803312 (2009).","journal-title":"Curr. Med. Chem."},{"key":"55185_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185654","volume":"12","author":"A Fukuda","year":"2017","unstructured":"Fukuda, A. et al. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS ONE. 12, e0185654. https:\/\/doi.org\/10.1371\/journal.pone.0185654 (2017).","journal-title":"PLoS ONE."},{"key":"55185_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-019-03827-0","volume":"84","author":"SE El-Agamy","year":"2019","unstructured":"El-Agamy, S. E., Abdel-Aziz, A. K., Esmat, A. & Azab, S. S. Chemotherapy and cognition: Comprehensive review on doxorubicin-induced chemobrain. Cancer Chemother. Pharmacol. 84, 1\u201314. https:\/\/doi.org\/10.1007\/s00280-019-03827-0 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"55185_CR9","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"MER O'Brien","year":"2004","unstructured":"O\u2019Brien, M. E. R. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15, 4410\u20134419. https:\/\/doi.org\/10.1093\/annonc\/mdh097 (2004).","journal-title":"Ann. Oncol."},{"key":"55185_CR10","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","volume":"71","author":"ST Duggan","year":"2011","unstructured":"Duggan, S. T. & Keating, G. M. Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma. Drugs. 71, 2531\u20132558. https:\/\/doi.org\/10.2165\/11207510-000000000-00000 (2011).","journal-title":"Drugs."},{"key":"55185_CR11","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1111\/febs.15583","volume":"288","author":"SY van der Zanden","year":"2021","unstructured":"van der Zanden, S. Y., Qiao, X. & Neefjes, J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS. 288, 6095\u20136111. https:\/\/doi.org\/10.1111\/febs.15583 (2021).","journal-title":"FEBS."},{"key":"55185_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120117","volume":"593","author":"V Makwana","year":"2021","unstructured":"Makwana, V. et al. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. Int. J. Pharm. 593, 120117. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120117 (2021).","journal-title":"Int. J. Pharm."},{"key":"55185_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1053\/j.seminoncol.2004.09.018","volume":"31","author":"NJ Robert","year":"2004","unstructured":"Robert, N. J. et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin. Oncol. 31, 106\u2013146. https:\/\/doi.org\/10.1053\/j.seminoncol.2004.09.018 (2004).","journal-title":"Semin. Oncol."},{"key":"55185_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3332\/ecancer.2008.111","volume":"2","author":"Y Yuan","year":"2008","unstructured":"Yuan, Y., Orlow, S. J., Curtin, J., Downey, A. & Muggia, F. Pegylated liposomal doxorubicin (PLD): Enhanced skin toxicity in areas of vitiligo. ECancer Med. Sci. 2, 111. https:\/\/doi.org\/10.3332\/ecancer.2008.111 (2008).","journal-title":"ECancer Med. Sci."},{"key":"55185_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/pharmaceutics15030893","volume":"15","author":"K Aloss","year":"2023","unstructured":"Aloss, K. & Hamar, P. Recent preclinical and clinical progress in liposomal doxorubicin. Pharmaceutics. 15, 893. https:\/\/doi.org\/10.3390\/pharmaceutics15030893 (2023).","journal-title":"Pharmaceutics."},{"key":"55185_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jgo.2013.07.004","volume":"4","author":"U Basso","year":"2013","unstructured":"Basso, U. et al. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (\u2265 70 years). J. Geriatr. Oncol. 4, 340\u2013345. https:\/\/doi.org\/10.1016\/j.jgo.2013.07.004 (2013).","journal-title":"J. Geriatr. Oncol."},{"key":"55185_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00280-015-2781-0","volume":"76","author":"P Chastagner","year":"2015","unstructured":"Chastagner, P. et al. Phase I study of non-pegylated liposomal doxorubicin in children with recurrent\/refractory high-grade glioma. Cancer Chemother. Pharmacol. 76, 425\u2013432. https:\/\/doi.org\/10.1007\/s00280-015-2781-0 (2015).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"55185_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061512","volume":"8","author":"SJ Veringa","year":"2013","unstructured":"Veringa, S. J. et al. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS ONE. 8, e61512. https:\/\/doi.org\/10.1371\/journal.pone.0061512 (2013).","journal-title":"PLoS ONE."},{"key":"55185_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.10201","volume":"94","author":"L Harris","year":"2002","unstructured":"Harris, L. et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 94, 25\u201336. https:\/\/doi.org\/10.1002\/cncr.10201 (2002).","journal-title":"Cancer."},{"key":"55185_CR20","first-page":"85","volume":"7","author":"PM Kanter","year":"1993","unstructured":"Kanter, P. M. et al. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): Comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo. 7, 85\u201395 (1993).","journal-title":"In Vivo."},{"key":"55185_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/10428190802043853","volume":"49","author":"G Visani","year":"2008","unstructured":"Visani, G. et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study. Leuk Lymphoma. 49, 1081\u20131086. https:\/\/doi.org\/10.1080\/10428190802043853 (2008).","journal-title":"Leuk Lymphoma."},{"key":"55185_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1525-1438.2003.13364.x","volume":"2","author":"JB Vermorken","year":"2003","unstructured":"Vermorken, J. B. The role of anthracyclines in second-line therapy of ovarian cancer. Int. J. Gynecol. Cancer. 2, 178\u2013184. https:\/\/doi.org\/10.1111\/j.1525-1438.2003.13364.x (2003).","journal-title":"Int. J. Gynecol. Cancer."},{"key":"55185_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13048-021-00790-4","volume":"14","author":"XR Li","year":"2021","unstructured":"Li, X. R., Zhu, Y., Zhang, G. N., Huang, J. M. & Pei, L. X. The impact of pegylated liposomal doxorubicin in recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials. J. Ovarian Res. 14, 42. https:\/\/doi.org\/10.1186\/s13048-021-00790-4 (2021).","journal-title":"J. Ovarian Res."},{"key":"55185_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133569","volume":"10","author":"M Xing","year":"2015","unstructured":"Xing, M., Yan, F., Yu, S. & Shen, P. Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: A Meta-analysis of ten randomized controlled trials. PLoS ONE. 10, e0133569. https:\/\/doi.org\/10.1371\/journal.pone.0133569 (2015).","journal-title":"PLoS ONE."},{"key":"55185_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000500204","volume":"42","author":"Z Mao","year":"2019","unstructured":"Mao, Z. et al. Comparisons of cardiotoxicity and efficacy of anthracycline-based therapies in breast cancer: A network meta-analysis of randomized clinical trials. Oncol. Res. Treat. 42, 405\u2013413. https:\/\/doi.org\/10.1159\/000500204 (2019).","journal-title":"Oncol. Res. Treat."},{"key":"55185_CR26","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","volume":"51","author":"N Yamaguchi","year":"2015","unstructured":"Yamaguchi, N. et al. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: A Bayesian network meta-analysis. Eur. J. Cancer. 51, 2314\u20132320. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.031 (2015).","journal-title":"Eur. J. Cancer."},{"key":"55185_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00277-014-2250-6","volume":"94","author":"I Wasle","year":"2015","unstructured":"Wasle, I. et al. Non-pegylated liposomal doxorubicin in lymphoma: Patterns of toxicity and outcome in a large observational trial. Ann. Hematol. 94, 593\u2013601. https:\/\/doi.org\/10.1007\/s00277-014-2250-6 (2015).","journal-title":"Ann. Hematol."},{"key":"55185_CR28","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.26355\/eurrev_201712_14036","volume":"21","author":"A Facciol\u00e0","year":"2017","unstructured":"Facciol\u00e0, A. et al. Kaposi\u2019s sarcoma in HIV-infected patients in the era of new antiretrovirals. Eur. Rev. Med. Pharmacol. Sci. 21, 5868\u20135869. https:\/\/doi.org\/10.26355\/eurrev_201712_14036 (2017).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"55185_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/030089160308900302","volume":"89","author":"L Cattel","year":"2003","unstructured":"Cattel, L., Ceruti, M. & Dosio, F. From conventional to stealth liposomes: A new frontier in cancer chemotherapy. Tumori. 89, 237\u2013249. https:\/\/doi.org\/10.1177\/030089160308900302 (2003).","journal-title":"Tumori."},{"key":"55185_CR30","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e15","volume":"31","author":"SJ Park","year":"2020","unstructured":"Park, S. J. et al. Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: A Korean multicenter retrospective cohort study. J. Gynecol. Oncol. 31, e15. https:\/\/doi.org\/10.3802\/jgo.2020.31.e15 (2020).","journal-title":"J. Gynecol. Oncol."},{"key":"55185_CR31","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cam4.3730","volume":"10","author":"JS Sancho","year":"2020","unstructured":"Sancho, J. S. et al. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients \u2265\u00a060 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Med. 10, 1314\u20131326. https:\/\/doi.org\/10.1002\/cam4.3730 (2020).","journal-title":"Cancer Med."},{"key":"55185_CR32","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","volume":"14","author":"A Chanan-Khan","year":"2003","unstructured":"Chanan-Khan, A. et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): Possible role in hypersensitivity reactions. Ann. Oncol. 14, 1430\u20131437. https:\/\/doi.org\/10.1093\/annonc\/mdg374 (2003).","journal-title":"Ann. Oncol."},{"key":"55185_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00280-008-0909-1","volume":"64","author":"J Sehouli","year":"2009","unstructured":"Sehouli, J. et al. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: Results of a German multicenter observational study. Cancer Chemother. Pharmacol. 64, 585\u2013591. https:\/\/doi.org\/10.1007\/s00280-008-0909-1 (2009).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"55185_CR34","doi-asserted-by":"publisher","DOI":"10.2174\/0115672018272162231116093143","author":"PR Guerrero","year":"2023","unstructured":"Guerrero, P. R. et al. Liposomal doxorubicin in vitro and in vivo assays in non-small cell lung cancer: A systematic review. Curr. Drug Deliv. https:\/\/doi.org\/10.2174\/0115672018272162231116093143 (2023).","journal-title":"Curr. Drug Deliv."},{"key":"55185_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/s0959-8049(01)00050-8","volume":"37","author":"I Judson","year":"2001","unstructured":"Judson, I. et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 37, 870\u2013877. https:\/\/doi.org\/10.1016\/s0959-8049(01)00050-8 (2001).","journal-title":"Eur. J. Cancer."},{"key":"55185_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/a:1014428720551","volume":"20","author":"KY Skubitz","year":"2002","unstructured":"Skubitz, K. Y. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer. Investig. New Drugs. 20, 101\u2013104. https:\/\/doi.org\/10.1023\/a:1014428720551 (2002).","journal-title":"Investig. New Drugs."},{"key":"55185_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/01.COC.0000020921.08768.1F","volume":"26","author":"WK Oh","year":"2003","unstructured":"Oh, W. K. et al. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: Feasibility and toxicity. Am. J. Clin. Oncol. 26, 312\u2013316. https:\/\/doi.org\/10.1097\/01.COC.0000020921.08768.1F (2003).","journal-title":"Am. J. Clin. Oncol."},{"key":"55185_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ygyno.2005.11.048","volume":"102","author":"PG Rose","year":"2006","unstructured":"Rose, P. G., Blessing, J. A., Lele, S. & Abulafia, O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 102, 210\u2013213. https:\/\/doi.org\/10.1016\/j.ygyno.2005.11.048 (2006).","journal-title":"Gynecol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55185-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55185-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55185-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T09:12:01Z","timestamp":1709543521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55185-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55185"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55185-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3237460\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"5 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5095"}}